| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 24 | 2022 | 983 | 2.740 |
Why?
|
| Blood Pressure | 22 | 2022 | 867 | 2.350 |
Why?
|
| Antihypertensive Agents | 14 | 2021 | 355 | 2.190 |
Why?
|
| Cardiovascular Diseases | 30 | 2021 | 1152 | 2.120 |
Why?
|
| Diabetic Retinopathy | 12 | 2021 | 73 | 1.960 |
Why?
|
| Mobility Limitation | 14 | 2020 | 221 | 1.920 |
Why?
|
| Obesity | 19 | 2023 | 1179 | 1.530 |
Why?
|
| Weight Loss | 16 | 2023 | 462 | 1.480 |
Why?
|
| Exercise | 17 | 2023 | 688 | 1.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2021 | 1477 | 1.360 |
Why?
|
| Aged | 79 | 2023 | 10637 | 1.280 |
Why?
|
| Renal Insufficiency, Chronic | 12 | 2022 | 298 | 1.260 |
Why?
|
| Hypoglycemic Agents | 9 | 2017 | 183 | 1.020 |
Why?
|
| Humans | 111 | 2023 | 32967 | 1.000 |
Why?
|
| Male | 82 | 2023 | 19754 | 0.950 |
Why?
|
| Interleukin-6 | 7 | 2020 | 241 | 0.930 |
Why?
|
| Female | 80 | 2023 | 20375 | 0.920 |
Why?
|
| Life Style | 12 | 2022 | 409 | 0.900 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2020 | 57 | 0.900 |
Why?
|
| Middle Aged | 57 | 2023 | 12203 | 0.870 |
Why?
|
| Losartan | 3 | 2019 | 64 | 0.800 |
Why?
|
| Exercise Therapy | 12 | 2023 | 282 | 0.730 |
Why?
|
| Sample Size | 4 | 2012 | 39 | 0.720 |
Why?
|
| Inflammation | 10 | 2020 | 542 | 0.660 |
Why?
|
| Thiazolidinediones | 4 | 2017 | 45 | 0.660 |
Why?
|
| Kidney Tubules | 5 | 2022 | 26 | 0.650 |
Why?
|
| Research Design | 8 | 2023 | 334 | 0.630 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 65 | 0.600 |
Why?
|
| Visual Acuity | 5 | 2021 | 77 | 0.600 |
Why?
|
| Glomerular Filtration Rate | 8 | 2022 | 310 | 0.590 |
Why?
|
| Self Efficacy | 4 | 2017 | 81 | 0.590 |
Why?
|
| Macular Edema | 4 | 2017 | 17 | 0.580 |
Why?
|
| Walking | 10 | 2023 | 212 | 0.580 |
Why?
|
| Patient Care Planning | 2 | 2020 | 58 | 0.560 |
Why?
|
| Aged, 80 and over | 23 | 2022 | 4065 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 412 | 0.550 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 115 | 0.550 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2019 | 136 | 0.550 |
Why?
|
| Risk Factors | 26 | 2021 | 4001 | 0.540 |
Why?
|
| Aging | 7 | 2019 | 955 | 0.480 |
Why?
|
| Patient Selection | 3 | 2019 | 281 | 0.470 |
Why?
|
| Follow-Up Studies | 14 | 2023 | 2287 | 0.450 |
Why?
|
| Motor Activity | 5 | 2015 | 327 | 0.440 |
Why?
|
| Overweight | 5 | 2022 | 263 | 0.440 |
Why?
|
| Stroke | 4 | 2023 | 610 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2020 | 541 | 0.430 |
Why?
|
| Body Mass Index | 8 | 2015 | 909 | 0.430 |
Why?
|
| Blood Pressure Determination | 6 | 2020 | 103 | 0.430 |
Why?
|
| Quality of Life | 7 | 2022 | 976 | 0.420 |
Why?
|
| Informed Consent | 1 | 2013 | 40 | 0.400 |
Why?
|
| Genetic Testing | 1 | 2013 | 99 | 0.400 |
Why?
|
| Body Image | 1 | 2012 | 19 | 0.380 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 26 | 0.380 |
Why?
|
| Self Concept | 1 | 2012 | 44 | 0.380 |
Why?
|
| Uncertainty | 1 | 2012 | 11 | 0.370 |
Why?
|
| Blood Glucose | 6 | 2020 | 495 | 0.360 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 97 | 0.340 |
Why?
|
| Ethnic Groups | 1 | 2013 | 474 | 0.340 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 308 | 0.340 |
Why?
|
| Osteoarthritis, Knee | 4 | 2022 | 82 | 0.330 |
Why?
|
| Albuminuria | 3 | 2022 | 180 | 0.330 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 416 | 0.330 |
Why?
|
| Risk Reduction Behavior | 3 | 2017 | 125 | 0.330 |
Why?
|
| Treatment Outcome | 13 | 2022 | 3460 | 0.310 |
Why?
|
| Longitudinal Studies | 6 | 2018 | 780 | 0.300 |
Why?
|
| Diet, Reducing | 6 | 2013 | 100 | 0.300 |
Why?
|
| Body Composition | 6 | 2019 | 391 | 0.290 |
Why?
|
| Double-Blind Method | 5 | 2019 | 543 | 0.280 |
Why?
|
| Bone Density | 6 | 2023 | 203 | 0.280 |
Why?
|
| Bone and Bones | 3 | 2023 | 94 | 0.280 |
Why?
|
| Pilot Projects | 5 | 2020 | 566 | 0.270 |
Why?
|
| Psychotherapy, Group | 2 | 2004 | 16 | 0.270 |
Why?
|
| Counseling | 2 | 2004 | 98 | 0.260 |
Why?
|
| Sacroiliac Joint | 1 | 2007 | 12 | 0.250 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 145 | 0.250 |
Why?
|
| Low Back Pain | 1 | 2007 | 47 | 0.250 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2018 | 121 | 0.250 |
Why?
|
| Incidence | 8 | 2020 | 1246 | 0.240 |
Why?
|
| Calcium Channel Blockers | 2 | 2018 | 51 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 765 | 0.240 |
Why?
|
| Pain Measurement | 2 | 2007 | 356 | 0.240 |
Why?
|
| Cognition | 3 | 2017 | 553 | 0.230 |
Why?
|
| Age Factors | 6 | 2018 | 1202 | 0.230 |
Why?
|
| Sex Factors | 6 | 2018 | 684 | 0.230 |
Why?
|
| Epilepsy | 2 | 2003 | 83 | 0.220 |
Why?
|
| Systole | 4 | 2020 | 98 | 0.220 |
Why?
|
| Sodium | 3 | 2019 | 42 | 0.220 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 883 | 0.220 |
Why?
|
| Troponin | 2 | 2022 | 112 | 0.220 |
Why?
|
| Troponin T | 2 | 2022 | 95 | 0.210 |
Why?
|
| Single-Blind Method | 7 | 2020 | 196 | 0.210 |
Why?
|
| Creatinine | 3 | 2020 | 199 | 0.210 |
Why?
|
| Gene Frequency | 1 | 2004 | 220 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 149 | 0.200 |
Why?
|
| Cataract Extraction | 2 | 2021 | 11 | 0.200 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 1581 | 0.200 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 388 | 0.200 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2003 | 5 | 0.200 |
Why?
|
| Depression | 2 | 2022 | 448 | 0.190 |
Why?
|
| Muscle Spasticity | 1 | 2003 | 24 | 0.190 |
Why?
|
| Biometry | 1 | 2002 | 13 | 0.190 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2003 | 35 | 0.190 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 38 | 0.190 |
Why?
|
| Time Factors | 7 | 2018 | 2195 | 0.190 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 53 | 0.190 |
Why?
|
| Heart Failure | 3 | 2022 | 761 | 0.180 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 44 | 0.180 |
Why?
|
| Health Education | 4 | 2020 | 162 | 0.180 |
Why?
|
| Fractures, Bone | 2 | 2015 | 162 | 0.180 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 61 | 0.180 |
Why?
|
| Adult | 17 | 2017 | 9586 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2014 | 63 | 0.180 |
Why?
|
| Hand Strength | 3 | 2020 | 102 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 837 | 0.170 |
Why?
|
| Cataract | 1 | 2021 | 8 | 0.170 |
Why?
|
| Disease Progression | 6 | 2020 | 594 | 0.170 |
Why?
|
| Diet | 3 | 2019 | 393 | 0.170 |
Why?
|
| Disability Evaluation | 3 | 2018 | 238 | 0.170 |
Why?
|
| Cause of Death | 3 | 2020 | 240 | 0.170 |
Why?
|
| Simvastatin | 2 | 2018 | 24 | 0.160 |
Why?
|
| Cystatin C | 1 | 2020 | 33 | 0.160 |
Why?
|
| Dementia | 1 | 2023 | 247 | 0.160 |
Why?
|
| Physicians | 1 | 2002 | 165 | 0.160 |
Why?
|
| Bayes Theorem | 3 | 2017 | 85 | 0.160 |
Why?
|
| Prognosis | 7 | 2020 | 1547 | 0.160 |
Why?
|
| Interleukin-18 | 1 | 2020 | 9 | 0.160 |
Why?
|
| Software | 2 | 2015 | 128 | 0.160 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 48 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 2002 | 280 | 0.160 |
Why?
|
| European Continental Ancestry Group | 3 | 2013 | 1163 | 0.150 |
Why?
|
| Disease Management | 2 | 2018 | 128 | 0.150 |
Why?
|
| Resistance Training | 2 | 2017 | 79 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 29 | 0.150 |
Why?
|
| United States | 7 | 2019 | 4132 | 0.150 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 487 | 0.150 |
Why?
|
| Hyperglycemia | 3 | 2014 | 81 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2020 | 187 | 0.140 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 35 | 0.140 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 47 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2018 | 15 | 0.140 |
Why?
|
| Diuretics | 1 | 2018 | 28 | 0.140 |
Why?
|
| Actigraphy | 1 | 2017 | 15 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2019 | 125 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2018 | 78 | 0.130 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2014 | 9 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 64 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 105 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2011 | 185 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 215 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2017 | 52 | 0.130 |
Why?
|
| Health Status | 3 | 2015 | 403 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2017 | 148 | 0.120 |
Why?
|
| Dyslipidemias | 2 | 2013 | 54 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 396 | 0.120 |
Why?
|
| Goals | 1 | 2015 | 35 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2013 | 460 | 0.110 |
Why?
|
| Managed Care Programs | 2 | 2005 | 41 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 682 | 0.110 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 7 | 0.110 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 9 | 0.110 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2005 | 72 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 30 | 0.110 |
Why?
|
| Sodium Channels | 2 | 2005 | 16 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2020 | 1469 | 0.110 |
Why?
|
| Medicaid | 2 | 2005 | 99 | 0.110 |
Why?
|
| Independent Living | 1 | 2015 | 105 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 3708 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 950 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2014 | 91 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 169 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 894 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 369 | 0.100 |
Why?
|
| Asian Americans | 1 | 2013 | 95 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2011 | 2338 | 0.100 |
Why?
|
| Medicare | 2 | 2005 | 213 | 0.100 |
Why?
|
| Educational Status | 1 | 2013 | 183 | 0.100 |
Why?
|
| African Americans | 2 | 2013 | 1425 | 0.100 |
Why?
|
| Photography | 1 | 2013 | 43 | 0.100 |
Why?
|
| Radius | 1 | 2013 | 26 | 0.100 |
Why?
|
| African Continental Ancestry Group | 2 | 2005 | 363 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 227 | 0.090 |
Why?
|
| Tibia | 1 | 2013 | 60 | 0.090 |
Why?
|
| Muscle Strength | 3 | 2020 | 159 | 0.090 |
Why?
|
| Vasodilator Agents | 2 | 2022 | 60 | 0.090 |
Why?
|
| Exercise Tolerance | 3 | 2015 | 129 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2022 | 80 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2014 | 370 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 576 | 0.080 |
Why?
|
| Lipids | 2 | 2023 | 230 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2012 | 180 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2018 | 1852 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 201 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 24 | 0.080 |
Why?
|
| Ligands | 1 | 2010 | 78 | 0.080 |
Why?
|
| Calcium | 1 | 2012 | 323 | 0.080 |
Why?
|
| Public Health | 1 | 2011 | 89 | 0.080 |
Why?
|
| Leptin | 2 | 2013 | 73 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 531 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2011 | 158 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 537 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 292 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2022 | 410 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 173 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 424 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 467 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 23 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1310 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 156 | 0.070 |
Why?
|
| North Carolina | 5 | 2013 | 1550 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 363 | 0.070 |
Why?
|
| Hispanic Americans | 1 | 2013 | 930 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2009 | 163 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 5 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.070 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2007 | 12 | 0.070 |
Why?
|
| Injections, Intra-Articular | 1 | 2007 | 16 | 0.060 |
Why?
|
| Physical Fitness | 2 | 2009 | 133 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 35 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2007 | 68 | 0.060 |
Why?
|
| Amiloride | 2 | 2005 | 5 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2007 | 104 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 895 | 0.060 |
Why?
|
| Prevalence | 2 | 2015 | 1002 | 0.060 |
Why?
|
| Gait | 1 | 2007 | 140 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 316 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 81 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2009 | 880 | 0.060 |
Why?
|
| Sampling Studies | 2 | 2003 | 44 | 0.060 |
Why?
|
| Adolescent | 5 | 2009 | 3643 | 0.060 |
Why?
|
| Oxalates | 1 | 2005 | 4 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 18 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2005 | 6 | 0.060 |
Why?
|
| C-Reactive Protein | 4 | 2011 | 240 | 0.060 |
Why?
|
| Child | 4 | 2009 | 2478 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 622 | 0.060 |
Why?
|
| Movement | 1 | 2005 | 51 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2005 | 23 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 73 | 0.060 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 40 | 0.060 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 19 | 0.060 |
Why?
|
| Calibration | 1 | 2004 | 28 | 0.050 |
Why?
|
| Markov Chains | 1 | 2004 | 32 | 0.050 |
Why?
|
| Hypoglycemia | 2 | 2015 | 42 | 0.050 |
Why?
|
| Enalapril | 1 | 2004 | 8 | 0.050 |
Why?
|
| Statistical Distributions | 1 | 2004 | 5 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 290 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2004 | 27 | 0.050 |
Why?
|
| Comorbidity | 2 | 2003 | 573 | 0.050 |
Why?
|
| Electrocardiography | 2 | 2020 | 637 | 0.050 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2004 | 47 | 0.050 |
Why?
|
| Physical Conditioning, Animal | 1 | 2004 | 35 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 126 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2004 | 94 | 0.050 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 5 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2003 | 2 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 4 | 0.050 |
Why?
|
| Rifampin | 1 | 2003 | 8 | 0.050 |
Why?
|
| Alleles | 1 | 2004 | 253 | 0.050 |
Why?
|
| Intestines | 1 | 2003 | 60 | 0.050 |
Why?
|
| Indiana | 1 | 2003 | 27 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2004 | 246 | 0.050 |
Why?
|
| Potassium | 1 | 2002 | 40 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2003 | 72 | 0.050 |
Why?
|
| Minerals | 1 | 2022 | 15 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2015 | 183 | 0.050 |
Why?
|
| Internet | 1 | 2004 | 201 | 0.050 |
Why?
|
| Genotype | 1 | 2004 | 731 | 0.050 |
Why?
|
| Faculty | 1 | 2002 | 15 | 0.050 |
Why?
|
| Child Behavior Disorders | 1 | 2002 | 12 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2003 | 92 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 599 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 109 | 0.040 |
Why?
|
| Adiposity | 2 | 2013 | 199 | 0.040 |
Why?
|
| Curriculum | 1 | 2002 | 211 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 492 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 195 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 34 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 98 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2020 | 74 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 762 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 125 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2019 | 18 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 71 | 0.040 |
Why?
|
| Weight Gain | 1 | 2019 | 112 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 125 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2019 | 191 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 308 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 136 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 29 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 135 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 148 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 302 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 30 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 188 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 65 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 2738 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 486 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 563 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 240 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 205 | 0.030 |
Why?
|
| Survivors | 1 | 2017 | 168 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 121 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 265 | 0.030 |
Why?
|
| Kidney | 1 | 2019 | 523 | 0.030 |
Why?
|
| Psychometrics | 1 | 2015 | 137 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 360 | 0.030 |
Why?
|
| Guideline Adherence | 2 | 2005 | 120 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2005 | 258 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2014 | 105 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2013 | 13 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 13 | 0.030 |
Why?
|
| Movement Disorders | 1 | 2013 | 26 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 24 | 0.030 |
Why?
|
| Muscle Development | 1 | 2013 | 49 | 0.020 |
Why?
|
| Community Health Centers | 1 | 2013 | 16 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2013 | 103 | 0.020 |
Why?
|
| Adiponectin | 1 | 2013 | 103 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2004 | 413 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 445 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2012 | 221 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 100 | 0.020 |
Why?
|
| Formularies as Topic | 1 | 2007 | 3 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 949 | 0.020 |
Why?
|
| Tablets | 1 | 2007 | 11 | 0.020 |
Why?
|
| Prescription Fees | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2007 | 10 | 0.020 |
Why?
|
| Drugs, Generic | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cost Control | 1 | 2007 | 18 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 49 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 181 | 0.020 |
Why?
|
| Exercise Test | 1 | 2007 | 226 | 0.020 |
Why?
|
| Medical Audit | 1 | 2005 | 16 | 0.010 |
Why?
|
| Knee | 1 | 2005 | 31 | 0.010 |
Why?
|
| Spironolactone | 1 | 2005 | 11 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 43 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 98 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 107 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 238 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 46 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2004 | 32 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2004 | 17 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2004 | 134 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 77 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 243 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 4 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 4 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 21 | 0.010 |
Why?
|
| Midazolam | 1 | 2003 | 10 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 229 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 79 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 29 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 213 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 92 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 94 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 101 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 296 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 189 | 0.010 |
Why?
|
| Aldosterone | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 247 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 56 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 783 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 174 | 0.010 |
Why?
|
| Child Behavior | 1 | 2002 | 24 | 0.010 |
Why?
|
| Renin | 1 | 2002 | 109 | 0.010 |
Why?
|
| Health Promotion | 1 | 2003 | 255 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1610 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 517 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 7599 | 0.010 |
Why?
|